NEW YORK (GenomeWeb News) – Arrayit Corp. today said that its majority-owned subsidiary Arrayit Diagnostics has filed a Form S-1 with the US Securities and Exchange Commission, which would allow it to become an independently traded company.

Upon going public, holders of every 3.34 shares of Arrayit Corp. stock will receive one share of Arrayit Diagnostics stock. Arrayit Corp.'s board approved the spin out of the diagnostics business late last year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.